Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Arch. Clin. Psychiatry (Impr.) ; 47(1): 19-24, Jan.-Feb. 2020. tab, graf
Article in English | LILACS | ID: biblio-1088743

ABSTRACT

Abstract Background Sleep disorders are common in psychiatric diseases. Panic disorder (PD) and generalized anxiety disorder (GAD) are two major anxiety disorders that are associated with sleep disorders. Objective We hypothesized that poor sleep quality continues in PD and GAD during remission. Therefore, in this study we aimed to compare the sleep quality of patients with PD and GAD to that of healthy controls. Methods The study included patients with PD (n = 42) and GAD (n = 40) who had been in remission for at least 3 months and healthy control volunteers (n = 45). The patients were administered the Pittsburgh Sleep Quality Index (PSQI), Beck Anxiety Inventory (BAI), and Beck Depression Inventory (BDI). Results The total PSQI scores of the GAD group were significantly increased in comparison to those of the PD (p = 0.009) and control (p < 0.001) groups. The rate of poor sleep quality in GAD during remission (77.5%) was greater than that of the PD (47.6%) and control (51.1%) groups (p = 0.011). Discussion GAD is a chronic and recurrent disease. In this study, it was found that the deterioration in sleep quality of patients with GAD may continue during remission. In the follow-up and treatment of patients, it is appropriate to question about sleep symptoms and to plan interventions according to these symptoms.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Young Adult , Anxiety Disorders/complications , Panic Disorder/complications , Sleep Initiation and Maintenance Disorders/etiology , Anxiety Disorders/drug therapy , Anxiety Disorders/epidemiology , Tobacco Use Disorder/complications , Remission Induction , Case-Control Studies , Chronic Disease , Cross-Sectional Studies , Follow-Up Studies , Panic Disorder/drug therapy , Panic Disorder/epidemiology , Selective Serotonin Reuptake Inhibitors/therapeutic use , Disease-Free Survival , Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use , Sleep Initiation and Maintenance Disorders/epidemiology
3.
Braz. j. med. biol. res ; 49(6): e4806, 2016. tab, graf
Article in English | LILACS | ID: biblio-951682

ABSTRACT

New generation antidepressant therapies, including serotonin-norepinephrine reuptake inhibitor (SNRIs), were introduced in the late 1980s; however, few comprehensive studies have compared the benefits and risks of various contemporary treatments for major depressive disorder (MDD) in young patients. A comprehensive literature search of PubMed, Cochrane, Embase, Web of Science, and PsycINFO databases was conducted from 1970 to January 2015. Only clinical trials that randomly assigned one SNRI or placebo to patients aged 7 to 18 years who met the diagnostic criteria for major depressive disorder were included. Treatment success, dropout rate, and suicidal ideation/attempt outcomes were measured. Primary efficacy was determined by pooling the risk ratios (RRs) of treatment response and remission. Acceptability was determined by pooling the RRs of dropouts for all reasons and for adverse effects as well as suicide-risk outcomes. Five trials with a total of 973 patients were included. SNRIs were not significantly more effective than placebo for treatment response but were for remission. The comparison of patients taking SNRIs that dropped out for all reasons and those taking placebo did not reach statistical significance. Significantly more patients taking SNRIs dropped out for adverse effects than those taking placebo. No significant difference was found in suicide-related risk outcomes. SNRI therapy does not display a superior efficacy and is not better tolerated compared to placebo in these young patients. However, duloxetine has a potential beneficial effect for depression in young populations, showing a need for further research.


Subject(s)
Humans , Male , Female , Child , Adolescent , Randomized Controlled Trials as Topic , Depressive Disorder, Major/drug therapy , Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use , Antidepressive Agents/therapeutic use , Placebos/therapeutic use , Cyclopropanes/therapeutic use , Desvenlafaxine Succinate/therapeutic use , Duloxetine Hydrochloride/therapeutic use , Milnacipran
4.
Professional Medical Journal-Quarterly [The]. 2015; 22 (4): 514-521
in English | IMEMR | ID: emr-162240

ABSTRACT

To demonstrate the efficacy of EMDR in complex multiple psychological trauma after failed drug treatment from selective serotonin reuptake inhibitor [SSRI] in a diagnosed case of post-traumatic stress disorder [PTSD]. Single participant of this case study, a sitting session judge of judicial governmental scaffold reported to this mental health tertiary care facility at his own accord with features of intense anxiety, depression, maladjustment issues and post- traumatic stress for a duration of several months. As a partial responder to full trial of SSRI he was enrolled for EMDR therapy to address his symptoms of intense anxiety, panic attacks, being overwhelmingly fearful, depressed, low self-esteem, inappropriate feelings of guilt, flashbacks, avoidance, nightmares, hyper-arousal and inability to perform as a judicial head in active war stricken area of northern Pakistan. Complete psychiatric evaluation was carried out and after the discontinuation of SSRIs he was scored on Impact of Event Scale [IES]. He fulfilled the diagnostic criteria for PTSD as evaluated by the English version of the PTSD module of the Structured Clinical Interview for DSM-IV administered once before commencement of EMDR. Safe place of the client was established and 8 staged protocol of EMDR was started with him. Multiple EMDR sessions were conducted. The case presented in this paper had multiple psychological trauma forms and failed drug treatment and yet it was observed that EMDR provided marked improvement in all the domains of his deficits and this was at a prompt speed as compared to cognitive behavioural therapy [CBT] which usually takes longer duration of therapy to achieve similar results. EMDR provides marked improvement in all domains of complex mental trauma and traumatic memories. Improvement attained was prompt and enduring as compared to other forms of established therapies and drug treatment indicating permanent changes happening at neurobiological levels of brain


Subject(s)
Humans , Stress Disorders, Post-Traumatic/therapy , Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use , Tertiary Healthcare , Depression/therapy , Anxiety/therapy
SELECTION OF CITATIONS
SEARCH DETAIL